Avadel Pharmaceuticals plc Ordinary Share (AVDL)
Avadel Pharmaceuticals plc is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of chronic diseases, primarily targeting sleep and neurological disorders. The company emphasizes leveraging its proprietary drug delivery technologies to improve patient outcomes and address unmet medical needs.
Company News
Law firm Monteverde & Associates is investigating the proposed sale of Avadel Pharmaceuticals to Alkermes, where shareholders will receive $18.50 per share plus a potential additional $1.50 contingent on FDA approval of LUMRYZâ„¢ by end of 2028.
The American Academy of Sleep Medicine Foundation and Avadel Pharmaceuticals have collaborated for five years to support early-career sleep researchers, providing mentorship, training, and funding for innovative sleep disorder research.
Avadel Pharmaceuticals reported strong Q2 2025 financial results, with GAAP revenue of $68.1 million, exceeding analyst expectations by 10.9%. The company achieved its first profitable quarter since LUMRYZ's launch, driven by increased patient adoption and strong commercial performance in narcolepsy treatment.
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.